The following is a recap of the presentations and posters from the CTOS conference held in Hawaii, with commentary by David Josephy. Dr. Michael Heinrich, David Josephy and Norman Scherzer CTOS 2017 Presentations [...]
Executive Director Norman Scherzer traveled to Lisbon, Portugal in November to attend the 21st annual meeting of the Connective Tissue Oncology Society (CTOS). CTOS is an annual conference which has grown since its inception [...]
In a recently published article in Nature Genetics, several prominent cancer researchers and GIST experts, led by Dr. Dr. Yuexiang Wang and including Dr. Jonathan Fletcher of Brigham & Women’s Hospital and Dr. Matthew van de Rijn of Stanford University Center, who are both members of the LRG’s research team, discuss new research findings that may potentially help identify GIST patients with a future high risk for metastases.
With the beautiful mountains of Switzerland and Lake Zurich in the background, 44 GIST Patient representatives from 28 countries and 32 patient groups/organizations convened in Zurich for the New Horizons GIST meeting from May 14-17, 2014.
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
A Cure is Within Our Grasp! It is amazing what happens when you change what doesn't work - Our Life Raft Group Research Team is a great example of this
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
